# A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus

> **NCT05030779** · EARLY_PHASE1 · UNKNOWN · sponsor: **Zhejiang University** · enrollment: 9 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus
- Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** Assigned Interventions CD19/BCMA CAR T-cells

## Key facts

- **NCT ID:** NCT05030779
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-10
- **Primary completion:** 2022-03-10
- **Final completion:** 2022-09-10
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2021-09-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05030779

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05030779, "A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05030779. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*